37 results
FWP
VANI
Vivani Medical Inc
6 Oct 14
Free writing prospectus
12:00am
globally due to unpreventable causes
Drivers of Mass Adoption R&D Argus II applicable to AMD with minor modifications Software upgrade (resolution … enhancement) R&D in development Cortical stimulation device (similar to Argus II) in development Regulatory Argus II approved in the US and EU for subset
8-K
EX-99.1
VANI
Vivani Medical Inc
13 Jan 15
Regulation FD Disclosure
12:00am
from Disruptive Technology
Nasdaq : EYES Drivers of Mass Adoption 9 R&D Regulatory Environment Reimbursement Centers of Excellence Scalability … IPO Original Argus II FDA Approval Software Improvements Approved R&D and Regulatory Milestones Current Argus II FDA Approval
Nasdaq : EYES R&D: Software
8-K
EX-99.1
VANI
Vivani Medical Inc
6 Aug 19
Second Sight Reports Second Quarter 2019 Financial Results
4:16pm
Ex 99.1
FOR IMMEDIATE RELEASE
Second Sight Reports Second Quarter 2019 Financial Results
-- R&D and Clinical Programs for Orion® Visual Cortical … year-to-date to support R&D and clinical research priorities;
Reduced commercial expenses by 41% in the second quarter of 2019 compared to the prior
8-K
EX-99.2
VANI
Vivani Medical Inc
2 Sep 22
Entry into a Material Definitive Agreement
3:42pm
, comprehensive loss is the same as net loss.
Research and development, and patent costs
Research and development (“R&D”) activities are focused … on pharmaceutical R&D, device R&D, regulatory consulting and manufacturing; the related costs consist primarily of clinical trial related costs, compensation
8-K
EX-99.1
VANI
Vivani Medical Inc
4 Sep 19
Regulation FD Disclosure
9:00am
to be larger
Growth Strategy Centered on Orion® Orion Core Competencies Research Execute Orion clinical and R&D programs Positive six- and 12-month results … of six subject U.S. Early Feasibility Study at UCLA and Baylor R&D iterating cortical prosthesis and external components in preparation for pivotal
8-K
EX-99.1
5mjl 9ody65l
8 Aug 18
Second Sight Reports Second Quarter 2018 Financial Results
5:14pm
8-K
EX-99.1
cfabuhtzm9yj
14 Nov 19
Second Sight Reports Third Quarter 2019 Financial Results
4:15pm
8-K
EX-99.1
zz0rotv
7 Nov 18
Second Sight Reports Third Quarter 2018 Financial Results
4:13pm
8-K
EX-99.1
ju3w3y54fdk nprz
23 May 19
Regulation FD Disclosure
4:00pm
8-K
EX-99.1
ebxha2ff xav79zhyri
14 Dec 18
Second Sight Completes $3 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
8:15am
8-K
EX-99.2
2scgwhzu 0zlsqg3vgtm
6 Jan 21
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
6:14am
DEFA14A
EX-99.2
rhv6z
6 Jan 21
Additional proxy soliciting materials
6:12am
8-K
EX-99.1
2i23uh 5l
21 Jun 18
Other Events
1:25pm
8-K
EX-99.1
pjkx4tjmohho90ja
24 May 18
Regulation FD Disclosure
12:16pm
8-K
EX-99.1
os8jej80rvcyhd1d
13 Mar 19
Second Sight Reports Fourth Quarter and Full Year 2018 Financial Results
5:12pm